• Arrowhead Pharmaceuticals agreed to acquire a U.S. FDA Rare Pediatric Disease Priority Review Voucher from an undisclosed third party.
• Voucher slated for a planned plozasiran sNDA to expand use into severe hypertriglyceridemia, with submission expected before end-2026.
• Priority Review would cut the FDA review goal to six months from 10 months under standard review.
• Deal closing is subject to the Hart-Scott-Rodino waiting period and customary conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein.